Boston Scientific (BSX) has shown consistent growth, with its stock outperforming its medical peers and rising 7.2% since the last earnings report. It has also been labeled as an incredible growth stock due to several factors, including strong organic sales growth, global expansion, innovation, and key acquisitions. The company has announced its Q2 2024 results and outpaced its earnings and revenue estimates, leading to the rise of its stock. It also had profitable Q1 and Q4 2023 results, surpassing analyst revenue forecasts and EPS estimates. Its Q2 earnings were boosted significantly owing to the strong performance of cardiovascular devices. Furthermore, Boston Scientific has completed a €2.0 billion offering of senior notes and announced an agreement to acquire Axonics, Inc., plus an acquisition of Silk Road Medical for $1.16 billion. The Silk Road Medical merger, however, has been delayed for review. The company's stock hit an all-time high at $79.46 and set a new one-year high at $79.59.
Boston Scientific Corp BSX News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 25 Aug 2024 19:45:49 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2